Publications by authors named "Laura Paglicawan"
Article Synopsis
- The study focuses on assessing the impact of buprenorphine-naloxone on mortality and remission rates among patients with opioid use disorder (OUD), amidst rising opioid-related deaths in the U.S.
- Using data from nearly 92 million medical records, the research compares outcomes between patients treated with buprenorphine-naloxone and a control group not receiving this treatment.
- Findings indicate that patients on buprenorphine-naloxone experienced 34% fewer deaths and approximately 1.9 times higher remission rates compared to those who did not receive the medication.
Epigallocatechin-3-gallate (EGCG) has been shown to attenuate obesity, fatty liver disease, hepatic inflammation and lipid profiles. Here, we validate the efficacy of EGCG in a murine model of non-alcoholic fatty liver disease (NAFLD) and extend the mechanistic insights. NAFLD was induced in mice by a high-fat diet (HFD) with 30% fructose.
View Article and Find Full Text PDF